Asthma, rhinitis, other respiratory diseasesInhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma☆,☆☆
Section snippets
Patients
Male and nonlactating female patients 12 years of age or older with OCS-dependent asthma were recruited from existing patient populations and through advertising at each of 21 medical centers. For eligibility, patients were required to have had severe persistent asthma for at least 12 months before enrollment,20 and they were required to have needed daily or alternate-day OCSs for asthma control for 5 or more of the 6 months before enrollment. Eligible patients were also required to have an FEV1
Patient characteristics
One hundred thirty-two patients were randomized. Demographic and baseline data were similar among groups (Table I).
Empty Cell Placebo MF-DPI 400 μg BID MF-DPI 800 μg BID Demographics No. of patients 43 46* 43 Sex (M/F) 24/19 22/24 16/27 White/African American/other 37/3/3 35/8/3 39/3/1 Mean age, y (range) 55 (26-79) 49 (13-83) 53 (22-77) Body weight, lb (range) 184 (132-282) 182 (120-275) 185 (120-286) Never smoked/not in 6 mo 23/20 29/17† 30/13
Discussion
We found a clinically significant OCS-sparing effect of MF administered by means of a dry powder inhaler. Compared with patients receiving placebo whose prednisone requirements increased after randomization, those receiving either dose of MF were able to significantly reduce their prednisone requirements, and a substantial proportion discontinued its use altogether. Coincident with prednisone reduction, MF-treated patients experienced significantly better pulmonary function and symptom scores,
References (25)
- et al.
Pharmaceutically-based severity stratification of an asthmatic population
Respir Med
(1999) - et al.
Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: a double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma
Chest
(1998) - et al.
Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma
J Allergy Clin Immunol
(1999) - et al.
Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis
J Allergy Clin Immunol
(1999) - et al.
Effects of budesonide by means of the Turbuhaler on the hypothalamic-pituitary-adrenal axis in asthmatic subjects: a dose-response study
J Allergy Clin Immunol
(1998) - et al.
Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients
Ann Allergy Asthma Immunol
(1996) - et al.
A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray
J Allergy Clin Immunol
(1996) - et al.
The inhibitory effects of topically active glucocorticoids on IL-4, IL- 5, and interferon-gamma production by cultured primary CD4+ T cells
J Allergy Clin Immunol
(1997) - et al.
Glucocorticoids inhibit proliferation and interleukin-4 and interleukin-5 secretion by aeroallergen-specific T-helper type 2 cell lines
Ann Allergy Asthma Immunol
(1998) - et al.
Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma
Ann Allergy Asthma Immunol
(2000)
Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler
Respir Med
A scale for the measurement of quality of life in adults with asthma
J Clin Epidemiol
Cited by (0)
- ☆
Supported by Schering-Plough.
- ☆☆
Reprint requests: James E. Fish, MD, Division of Pulmonary and Critical Care Medicine, Jefferson Medical College, 1025 Walnut St, Room 805, Philadelphia, PA 19107.